1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Innate Pharma
  6. Company
    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
Real-time Euronext Paris  -  11:35 2022-08-09 am EDT
2.696 EUR   -1.17%
08/01SECTOR UPDATE : Health Care Stocks Lean Lower Premarket Monday
MT
08/01Wall Street Futures Consolidate After Strong End to July
MT
08/01SECTOR UPDATE : Health Care
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Innate Pharma
Innate Pharma is a clinical-stage biotechnology company specialized in immuno-oncology and dedicated to improving cancer treatment through innovative therapeutic antibodies that exploit the immune system. Innate Pharma's broad antibody portfolio includes several potential «first-in-class» candidates in clinical and preclinical stages in cancers with high medical need. Innate Pharma is a pioneer in the understanding of NK cell biology and has developed expertise in the tumor microenvironment and tumor antigens, as well as in antibody engineering. Its innovative approach has enabled it to build a diversified proprietary portfolio and to forge alliances with leading biopharmaceutical companies such as Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi as well as a multi-product partnership with AstraZeneca. Revenues break down by source of income as follows:

- government financing for research expenditure (51%);

- revenues from collaboration and licensing agreements (49%);

At the end of 2021, the company held a portfolio of 6 products in clinical development including 1 in phase III (Monalizumab for the treatment of cancer), 2 in phase II (Lacutamab for the treatment of cutaneous T-cell lymphoma and IPH4102 for the treatment of bullous pemphigoid) and 3 in phase I (IPH5401 and IPH5301 for the treatment of solid tumors, and IPH6101 for the treatment of relapsed or refractory acute myeloid leukemia), and 7 in preclinical development phase.

Number of employees : 215 people.
Sales per Business
20202021Delta
Therapeutic Antibodies70.45100%24.70100% -64.94%
EUR in Million
Sales per region
20202021Delta
France70.45100%24.70100% -64.94%
EUR in Million
Managers
Name Title Age Since
Mondher Mahjoubi, Dr. Chairman-Executive Board & Chief Executive Officer 63 2016
Frederic Lombard Chief Financial Officer - 2021
Eric Vivier, Dr. Chief Scientific Officer & Senior Vice President 58 2018
Odile Belzunce Senior VP-Compliance, IT & Operations 41 2019
Joyson Joseph Karakunnel, Dr. Chief Medical Officer & Executive Vice President 51 2020
Henry Wheeler Head-Investor Relations & Communications - 2022
Yannis Morel, Dr. EVP-Business Development & Portfolio Strategy 48 -
Guillaume Gimonet Senior Director-Launch Excellence - -
Nicola Beltraminelli Chief Development Officer & Vice President - 2022
Odile Laurent Director-Human Resources & Vice President 60 2020
Members of the board
Name Title Age Since
Hervé Eloi Dominique Brailly, Dr. Chairman-Supervisory Board 60 1999
Mondher Mahjoubi, Dr. Chairman-Executive Board & Chief Executive Officer 63 2016
Irina Staatz-Granzer, Dr. Vice Chairman-Supervisory Board 62 2012
Véronique Chabernaud, Dr. Independent Member-Supervisory Board 60 2015
Jean-Yves Blay, Dr. Independent Member-Supervisory Board 59 2018
Pascale Boissel Independent Member-Supervisory Board 55 2020
Gilles Brisson Member-Supervisory Board 69 2016
Olivier Martinez, Dr. Member-Supervisory Board 51 2021
Sally Bennett, Dr. Member-Supervisory Board - 2022
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 79,542,627 59,845,212 75.2% 18,575 0.0% 75.2%
Stock B 0 7,581 0 0.0% 0 0.0%
Stock C 0 6,514 0 0.0% 0 0.0%
Shareholders
NameEquities%
Novo Nordisk A/S 9,817,546 12.3%
AstraZeneca PLC 7,485,500 9.39%
Bpifrance Participations SA /PRIVATE EQUITY/ 6,389,406 8.01%
Hervé Eloi Dominique Brailly 920,284 1.15%
Mondher Mahjoubi 406,621 0.51%
BlackRock Fund Advisors 318,922 0.40%
La Française Asset Management SAS 209,000 0.26%
Abeille Asset Management SA 183,364 0.23%
Eric Vivier 150,501 0.19%
OFI Asset Management SA 140,000 0.18%
Holdings
NameEquities%Valuation
INNATE PHARMA (IPH) 18,575 0.023% 49,791 USD
Markets and indexes
- PEA / SRD eligible : YES / YES
- Compartiment B
- CAC Small / CAC All Shares, CAC All-Tradable, CAC Mid Small, CAC PME, EnterNext© PEA-PME 150, Next Biotech, PEA, PEA-PME, Tech 40
Stock Exchange Codes
- Bloomberg Code :  IPH:FP
- Reuters Code :  IPH.PA
- Datastream Code :  
Company contact information
Innate Pharma
117 Avenue de Luminy
BP 30191
FR-13009 Marseille

Phone : +33 (0)4 30 30 30 30
Fax : +33 (0)4 30 30 30 00
web site : http://www.innate-pharma.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Innate Pharma